Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Small-molecule CD73 inhibitors for the immunotherapy of cancer: a patent and literature review (2017–present)
Alessio Nocentini, Clemente Capasso, Claudiu T. Supuran
Expert Opinion on Therapeutic Patents (2021) Vol. 31, Iss. 10, pp. 867-876
Closed Access | Times Cited: 25

Showing 25 citing articles:

CD39/CD73/A2AR pathway and cancer immunotherapy
Chenglai Xia, Shuanghong Yin, Kenneth K.W. To, et al.
Molecular Cancer (2023) Vol. 22, Iss. 1
Open Access | Times Cited: 142
Cancer Therapeutic Targeting of Hypoxia Induced Carbonic Anhydrase IX: From Bench to Bedside
Paul C. McDonald, Shawn C. Chafe, Claudiu T. Supuran, et al.
Cancers (2022) Vol. 14, Iss. 14, pp. 3297-3297
Open Access | Times Cited: 76
The Clinical Significance of CD73 in Cancer
Niklas Bach, Riekje Winzer, Eva Tolosa, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 14, pp. 11759-11759
Open Access | Times Cited: 27
Analysis of a large cohort of pancreatic cancer transcriptomic profiles to reveal the strongest prognostic factors
Máté Posta, Balázs Győrffy
Clinical and Translational Science (2023) Vol. 16, Iss. 8, pp. 1479-1491
Open Access | Times Cited: 22
Combining High-Z Sensitized Radiotherapy with CD73 Blockade to Boost Tumor Immunotherapy
Qian Chen, Jing Chen, Qingqing Zhang, et al.
ACS Nano (2023) Vol. 17, Iss. 13, pp. 12087-12100
Closed Access | Times Cited: 16
Protein kinase inhibitor ceritinib blocks ectonucleotidase CD39 – a promising target for cancer immunotherapy
Laura Schäkel, Salahuddin Mirza, Riekje Winzer, et al.
Journal for ImmunoTherapy of Cancer (2022) Vol. 10, Iss. 8, pp. e004660-e004660
Open Access | Times Cited: 21
CD73, a Promising Therapeutic Target of Diclofenac, Promotes Metastasis of Pancreatic Cancer through a Nucleotidase Independent Mechanism
Weishuai Liu, Xiaozhou Yu, Yudong Yuan, et al.
Advanced Science (2022) Vol. 10, Iss. 6
Open Access | Times Cited: 20
Roxadustat (FG-4592) protects against ischaemia-induced acute kidney injury via improving CD73 and decreasing AIM2 inflammasome activation
Huan Yang, Yong Wu, Ming Cheng, et al.
Nephrology Dialysis Transplantation (2022) Vol. 38, Iss. 4, pp. 858-875
Closed Access | Times Cited: 18
Integrated multi-omics analysis identifies CD73 as a prognostic biomarker and immunotherapy response predictor in head and neck squamous cell carcinoma
Ao Shen, Yafen Ye, Fan Chen, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 16
Second‐Generation CD73 Inhibitors Based on a 4,6‐Biaryl‐2‐thiopyridine Scaffold
Rayane Ghoteimi, A. Braka, Céline Rodriguez, et al.
ChemMedChem (2023) Vol. 18, Iss. 7
Open Access | Times Cited: 9
Epithelial–mesenchymal transition to Mitigate Age-Related Progression in Lung Cancer
Riya Thapa, Saurabh Gupta, Gaurav Gupta, et al.
Ageing Research Reviews (2024) Vol. 102, pp. 102576-102576
Closed Access | Times Cited: 3
Tumor Microenvironment Responsive CD8+ T Cells and Myeloid‐Derived Suppressor Cells to Trigger CD73 Inhibitor AB680‐Based Synergistic Therapy for Pancreatic Cancer
Qiangda Chen, Hanlin Yin, Junyi He, et al.
Advanced Science (2023) Vol. 10, Iss. 33
Open Access | Times Cited: 8
Structure–Activity Relationship of 3-Methylcytidine-5′-α,β-methylenediphosphates as CD73 Inhibitors
Mirko Scortichini, Riham M. Idris, Susanne Moschütz, et al.
Journal of Medicinal Chemistry (2022) Vol. 65, Iss. 3, pp. 2409-2433
Open Access | Times Cited: 12
Targeting ecto-5′-nucleotidase: A comprehensive review into small molecule inhibitors and expression modulators
Gustavo Machado das Neves, Luciano Porto Kagami, Ana Maria Oliveira Battastini, et al.
European Journal of Medicinal Chemistry (2022) Vol. 247, pp. 115052-115052
Closed Access | Times Cited: 9
Purinergic pathways and their clinical use in the treatment of acute myeloid leukemia
Huijuan Wang, Yujie Wei, Na Wang
Purinergic Signalling (2024)
Closed Access | Times Cited: 1
CD73 promotes non–small cell lung cancer metastasis by regulating Axl signaling independent of GAS6
Jianjie Zhu, Wenwen Du, Yuanyuan Zeng, et al.
Proceedings of the National Academy of Sciences (2024) Vol. 121, Iss. 43
Open Access | Times Cited: 1
Behavioral factors to modulate immunotherapy efficacy in cancer
Chiara Jongerius, Louis Vermeulen, Marjolein van Egmond, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 5
Anti-inflammatory potency of novel ecto-5′-nucleotidase/CD73 inhibitors in astrocyte culture model of neuroinflammation
Katarina Mihajlović, Marija Adžić, Milorad Dragić, et al.
European Journal of Pharmacology (2023) Vol. 956, pp. 175943-175943
Closed Access | Times Cited: 2
Generation of Non-Nucleotide CD73 Inhibitors Using a Molecular Docking and 3D-QSAR Approach
Swapnil P. Bhujbal, Jung‐Mi Hah
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 23, pp. 12745-12745
Open Access | Times Cited: 4
Targeting CD73 for anti-tumor immunity
Shi Liu, Pierre-Antoine Laurent, Éric Deutsch, et al.
Elsevier eBooks (2024)
Closed Access
Chronobiologically Targeted Anticancer Strategy: Synergistic Inhibition of CD39 and CD73 with Adenosine Receptor Agonists
Ismail Celil Haskologlu, Emine Erdag, Damla Ülker, et al.
Interdisciplinary cancer research (2024)
Closed Access
Discovery of the ((diaryl)methyl)phosphonic acid derivatives as novel CD73 inhibitors
Wenyu Yang, Xi Chen, Xiang-Li Ning, et al.
Journal of Heterocyclic Chemistry (2023) Vol. 60, Iss. 12, pp. 1959-1975
Closed Access | Times Cited: 1
CD73 Inhibitors as Antitumor Agents
Clemente Capasso, Alessio Nocentini, Claudiu T. Supuran
Topics in medicinal chemistry (2023), pp. 331-343
Closed Access
Bacterial Ectonucleotidases: Underexplored Antibacterial Drug Targets
Alessio Nocentini, Clemente Capasso, Claudiu T. Supuran
Topics in medicinal chemistry (2023), pp. 345-354
Closed Access
CD73 (5′-Ectonucleotidase)
Claudiu T. Supuran, Clemente Capasso
Elsevier eBooks (2023), pp. 283-292
Closed Access
Page 1

Scroll to top